论文部分内容阅读
目的:探讨达格列净对2型糖尿病患者心血管和肾功能的保护作用。方法:选取济宁医学院附属湖西医院（单县中心医院）2019年1-12月收治的血糖控制不佳的2型糖尿病患者200例，采用随机数字表法分为对照组（n n=100例）、观察组（n n=100例）。两组配合饮食控制及运动治疗，对照组采取二甲双胍治疗，观察组采用达格列净治疗。两组疗程12周。比较两组治疗前后血糖、血脂、血压、体质量指数、心功能及肾功能指标，观察两组不良反应。n 结果:治疗后，两组血糖、血脂、体质量指数、心功能及肾功能指标均较治疗前改善（均n P<0.05），观察组治疗后空腹血糖、餐后2 h血糖、糖化血红蛋白、收缩压、舒张压、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、体质量指数、左心室舒张末期内径、血肌酐、尿酸、胱抑素C分别为（6.48±0.72）mmol/L、（8.03±0.77）mmol/L、（6.16±0.63）%、（126.03±3.86）mmHg、（75.62±2.87）mmHg、（3.83±0.17）mmol/L、（2.21±0.36）mmol/L、（2.34±0.15）mmol/L、（23.03±0.55）kg/mn 2、（52.10±2.13）mm、（39.97±1.62）μmol/L、（237.17±20.34）μmol/L、（0.64±0.06）mg/L，均显著低于对照组的（8.01±0.84）mmol/L、（10.03±0.90）mmol/L、（7.30±0.72）%、（130.06±4.79）mmHg、（79.60±3.19）mmHg、（4.67±0.37）mmol/L、（2.51±0.57）mmol/L、（2.74±0.19）mmol/L、（24.03±0.60）kg/mn 2、（57.22±1.74）mm、（80.00±6.88）μmol/L、（281.62±40.52）μmol/L、（0.76±0.09）mg/L（n t=13.850、16.866、11.933、6.549、9.263、20.879、4.469、16.982、12.410、18.634、10.626、9.804、18.876，均n P<0.001）；观察组治疗后高密度脂蛋白、左心室射血分数和6 min步行试验分别为（2.47±0.15）mmol/L、（39.97±1.62）%、（366.50±17.74）m，均显著优于对照组的（1.70±0.20）mmol/L、（36.77±1.21）%、（323.70±12.48）m（n t=30.255、16.435、19.733，均n P0.05）。n 结论:达格列净通过降低2型糖尿病患者血糖、血压、血脂、血肌酐、血尿酸及体质量指数来发挥保护心血管及肾功能的作用。“,”Objective:To investigate the protective effect of dagglitazine on cardiovascular and renal function in patients with type 2 diabetes mellitus.Methods:A total of 200 patients with type 2 diabetes patients with poor blood glucose control who received treatment in Huxi Hospital Affiliated to Jining Medical University (Shanxian Central Hospital) from January to December 2019 were included in this study. They were randomly assigned to receive treatment with either metformin (n n = 100, control group) or dagglitazine (n n = 100, observation group) based on diet control and exercise therapy for 12 weeks. Before and after treatment, blood glucose, blood lipid, blood pressure, body mass index, cardiac function and renal function were compared between the control and observation groups. Adverse reactions were also monitored in each group.n Results:After treatment, blood glucose, blood lipid, body mass index, cardiac function and renal function in each group were improved compared with before treatment (all n P < 0.05). Fasting blood glucose, 2-h postprandial blood glucose, glycosylated hemoglobin, systolic blood pressure, diastolic blood pressure, total cholesterol, triglyceride, low density lipoprotein cholesterol, body mass index, left ventricular end diastolic diameter, serum creatinine, uric acid and cystatin C in the observation group were (6.48 ± 0.72) mmol/L, (8.03 ± 0.77) mmol/L, (6.16 ± 0.63)%, (126.03 ± 3.86) mmHg, (75.62 ± 2.87) mmHg, (3.83 ± 0.17) mmol/L, (2.21 ± 0.36) mmol/L, (2.34 ± 0.15) mmol/L, (23.03 ± 0.55) kg/m n 2, (52.10 ± 2.13) mm, (39.97 ± 1.62) μmol/L, (237.17 ± 20.34) μmol/L, (0.64 ± 0.06) mg/L, respectively, which were significantly lower than (8.01 ± 0.84) mmol/L, (10.03 ± 0.90) mmol/L, (7.30 ± 0.72)%, (130.06 ± 4.79) mmHg, (79.60 ± 3.19) mmHg, (4.67 ± 0.37) mmol/L, (2.51 ± 0.57) mmol/L, (2.74 ± 0.19) mmol/L, (24.03 ± 0.60) kg/mn 2, (57.22 ± 1.74) mm, (80.00 ± 6.88) μmol/L, (281.62 ± 40.52) μmol/L, (0.76 ± 0.09) mg/L, n t = 13.850, 16.866, 11.933, 6.549, 9.263, 20.879, 4.469, 16.982, 12.410, 18.634, 10.626, 9.804, 18.876, all n P < 0.001). After treatment, high density lipoprotein cholesterol, left ventricular ejection fraction, and the average distance walked by patients during the 6-min walk test in the observation group were (2.47 ± 0.15) mmol/L, (39.97 ± 1.62)%, (366.50 ± 17.74) m, which were significantly superior to those in the control group [(1.70 ± 0.20) mmol/L, (36.77 ± 1.21)%, (323.70 ± 12.48) m, n t = 30.255, 16.435, 19.733, all n P 0.05).n Conclusion:Dagglitazine protects cardiovascular and renal function by reducing blood glucose, blood pressure, blood lipid, serum creatinine, serum uric acid levels and decreasing body mass index in patients with type 2 diabetes mellitus.